Multi-center, double-blind, placebo-controlled, randomized, parallel group study to evaluate the effects of different doses of SH T 00127B [asoprisnil] in women with treatment-resistant menorrhagia aged 30 to 55 years after daily oral administration of multiple doses for 35 up to 50 days
Phase of Trial: Phase II
Latest Information Update: 11 Dec 2008
At a glance
- Drugs Asoprisnil (Primary)
- Indications Menorrhagia
- Focus Therapeutic Use
- Sponsors Bayer
- 11 Dec 2008 Last checked against ClinicalTrials.gov record.
- 21 Jul 2006 New trial record.